厄洛替尼联合贝伐单抗治疗晚期非小细胞肺癌的临床观察

Clinical observation of combined erlotinib with bevacizumab in advanced non-small cell lung cancer patients

目的观察厄洛替尼联合贝伐单抗治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法选取35例晚期非小细胞肺癌患者,给予厄洛替尼150mg/d口服,贝伐单抗15mg/kg静脉滴注,21天为1个周期,直至疾病进展,观察记录近期疗效及毒副反应。结果 35例患者中完全缓解0例,部分缓解16例,稳定12例,进展7例,疾病控制率为80%。主要毒副反应为皮疹、腹泻以及出血,发生率分别为77.1%、42.9%、22.9%。结论厄洛替尼联合贝伐单抗能有效治疗晚期非小细胞肺癌,且毒副反应较轻。

Objective To evaluate the curative effect and adverse reactions of combined edotinib with bevacizumab in advanced non-small cell lung cancer patients. Methods Thirty-five patients with advanced NSCLC were enrolled in this study. Edotinib （150mg） was orally administered daily, and hevacizumab （15mg/kg） was injected, 21 days as a cycle. Re- suits There were no patient who got complete remission, sixteen patients who got partial remission and twelve patients whose condition were stable, the disease control rate was 80%. The major adverse reactions of this study were skin rash, diarrhea and bleeding, the incidence rate of them were 77.1%,42.9% and 22.9% separately. Conclusion Combined erlotinib with bevacizumab are effective in the treatment of advanced NSCLC, and the adverse reactions are minor.